News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ)'s Combo Diabetes Drug Held Up By FDA


12/16/2013 7:42:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The FDA has knocked back a combination diabetes product based on Johnson & Johnson's canagliflozin and metformin because it wants more data on dosing. The regulator wants to make sure the canagliflozin component of the the twice-daily combination is comparable to the once-daily formulation of the drug, which was approved under the Invokana brand name earlier this year. Canagliflozin was the first compound in the brand new sodium glucose co-transporter 2 (SGLT2) inhibitor class to be approved for marketing in the US.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES